GlassScriptPhysician profile
Vinit Kumar Jha
NPI 1710561527
$4,614.07
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.05 · 2022: $719 · 2023: $1,859 · 2024: $2,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,875.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,875.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,005.18 | 2022-2024 | Otezla, Enbrel, Evenity |
| Abbvie INC. | $649.09 | 2022-2024 | |
| Glaxosmithkline, LLC. | $430.85 | 2022-2024 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $361.75 | 2021-2024 | Ofev, Cyltezo |
| Janssen Biotech, INC. | $268.22 | 2023-2024 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $264.89 | 2023-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $203.86 | 2023-2024 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $192.17 | 2024 | |
| Ucb, INC. | $152.11 | 2022-2024 | Cimzia |
| Alexion Pharmaceuticals, INC. | $141.84 | 2023-2024 | Strensiq, Ultomiris, Soliris |
| Pfizer INC. | $138.02 | 2023-2024 | |
| Organon LLC | $78.62 | 2023-2024 | Hadlima, Renflexis |
| Aurinia Pharma U.S., INC. | $75.50 | 2023-2024 | Lupkynis |
| Sobi, INC | $75.32 | 2023-2024 | |
| Horizon Therapeutics Plc | $72.99 | 2023 | Krystexxa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $68.60 | 2023-2024 | Tymlos |
| Mylan Institutional INC. | $59.26 | 2023 | Hulio |
| Genzyme Corporation | $48.87 | 2023-2024 | |
| Actelion Pharmaceuticals US, INC. | $46.70 | 2023-2024 | Uptravi, Opsumit |
| Sandoz INC. | $42.43 | 2023-2024 | Hyrimoz |
| Mallinckrodt Hospital Products INC. | $36.85 | 2024 | Acthar |
| E.R. Squibb & Sons, L.L.C. | $31.43 | 2023-2024 | Orencia |
| Fresenius Kabi USA, LLC | $30.79 | 2023-2024 | Idacio |
| Biocon Biologics INC | $27.35 | 2024 | Hulio |
| Tersera Therapeutics LLC | $26.83 | 2024 | Quzyttir |
| Teleflex LLC | $25.14 | 2022 | |
| Ani Pharmaceuticals, INC. | $22.90 | 2024 | Purified Cortrophin Gel |
| Bioventus LLC | $21.56 | 2023 | Durolane |
| Octapharma USA, INC. | $14.95 | 2024 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vinit Jha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.